ReviewInnere Medizin (Heidelberg, Germany)2026
[Histology and more-modern nephropathology].
Review in Innere Medizin (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal biopsy remains the gold standard for diagnosing kidney disease; it is performed in accordance with generally accepted clinical indications and evaluated using well-established histopathological techniques. This is usually done by specialized renal pathology departments, which have the necessary special techniques at their disposal, such as special staining, immunofluorescence or immunohistology, and, above all, electron microscopy, which are not available at all pathology institutes. In addition to classic histology-based analysis methods, new modern complementary methods are increasingly being developed, including molecular and digital techniques, which are intended to enable more precise, pathogenetically oriented diagnosis, better prognosis assessment, and, increasingly, therapy-guided decisions. As in medicine as a whole, trends are moving away from classic, purely morphological assessments toward integrated, digital, and molecular diagnostics, which are more accurate, improve prognoses, and enable more targeted therapies.
Indexed as
Identifiers
41973225What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.